ESG
Janssen, BMS and Roche among companies to support Leukaemia Foundation’s patient resource
The Leukaemia Foundation is proud to unveil a new website providing over 900 pages of the latest trusted information about blood cancer, custom-built specifically with Australian blood cancer patients and their family’s needs in mind.
The 18-month long website project has come together through the efforts of a Leukaemia Foundation Steering Committee, Working Group and generous funding from Perpetual Trustees and pharmaceutical companies Janssen, Bristol-Myers Squibb / Celgene, Novartis, AstraZeneca, Roche and MSD.
Designed to inform and empower patients and their families right throughout their experience with blood cancer, the new website includes extensive information on the different types of blood cancers, the latest news on research, trials, tests and treatments as well as personal stories from those who have a lived experience with blood cancer.
Leukaemia Foundation Acting CEO Alex Struthers said the Leukaemia Foundation is driven by the need to improve the lives of people affected by blood cancer by ensuring they have access to trusted, credible information and resources.
“Drawing on more than four decades of experience and knowledge, we have built a patient-centric resource that will transform how Australians living with blood cancer access disease, treatment and wellness information,” Ms Struthers said.
Google trends confirm that in Australia the peak times people search online for information about blood cancer is between 1am – 4am every single day.
“Now more than ever, Australians affected by blood cancer need accurate information that is relevant, relatable and easily accessible, at any time of the day. People living with blood cancer will be able to learn and digest information about their disease and treatment journey at their own pace and at a time that is convenient for them,” Ms Struthers said.
Over the past year, the Leukaemia Foundation website has had more than 1.5 million-page views, with one million of those visitors accessing disease information.
“Blood cancer comes with so many questions and unknowns. Our supporters have made accessing information possible by ensuring families around the country find the credible, relevant facts they’re searching for,” she said.
“Health care professionals and stakeholders in the blood cancer community will know that when they refer a patient to the Leukaemia Foundation website, they will be accessing credible information which meets the health literacy levels for all patients,” Ms Struthers said.
News & Trends - MedTech & Diagnostics

Medtech, academia and government unite: Breaking down silos to deliver the power and promise of digital health to patients
MedTech & Diagnostics News: In an interview with Health Industry Hub, Annette Schmiede, CEO of Digital Health Cooperative Research Centre […]
MoreNews & Trends - MedTech & Diagnostics

Two-decade evolution of robotic surgery in Australia’s medical landscape
MedTech & Diagnostics News: In the past two decades, what was once deemed impossible in surgery has now become a […]
MoreNews & Trends - Pharmaceuticals

World-first in IVF: Merging AI and genomics to optimise treatment response for Australians
Pharma News: A world-first Australian IVF study exploring genome sequencing has garnered enthusiastic reception from its collaborative research partners. Securing […]
MoreNews & Trends - Pharmaceuticals

PBS listing marks first oral therapy for childhood arthritis
Pharma News: The first oral Janus kinase (JAK) inhibitor, Pfizer’s Xeljanz (tofacitinib), has been listed on the Pharmaceutical Benefits Scheme […]
More